EACR 2025 |
Experience Live Single-Cell Functional Insights with Beacon Discoveryâ„¢ for Oncology & Immunotherapy Research
Overview
Imagine capturing high-dimensional, time-resolved functional data at single-cell resolution—all in an affordable, benchtop solution. Now, integrate these deep functional insights with transcriptomics and genomics sequencing data from the same single cells. Bruker Cellular Analysis presents Beacon Discovery, a platform designed to accelerate oncology and immunotherapy research. With an intuitive interface, automated workflows, and customizable experiment capabilities, Beacon Discovery empowers researchers to characterize immune responses, optimize antibody discovery, and advance cell therapy development. Join this session to explore how Beacon Discovery streamlines the discovery, validation, and translation of cell-based therapies.
Speakers
Dr. Patrick Schmidt
Group Leader Transgenic T Cell Therapy, DKFZ
Dr. rer. nat. Patrick Schmidt is a senior scientist with 20 years of experience in CAR-T research. He completed his undergraduate studies in Developmental Biology and Genetics at the University of Cologne, earning his diploma in 2005. He conducted his Ph.D. research in Hinrich Abken's lab, developing anti-melanoma CARs, and finished in 2008. This was followed by a three-year DFG fellowship-sponsored postdoctoral position at the École Polytechnique Fédérale de Lausanne in Switzerland. In 2014, Patrick joined the Department of Medical Oncology at the National Center of Tumor Diseases Heidelberg, led by Dirk Jäger. He is currently a research group leader and head of ATMP manufacturing, affiliated with the University Hospital Heidelberg and the German Cancer Research Center.
Tiago Santos, PhD
Market Development Executive, Bruker Cellular Analysis
Tiago Santos has over five years of experience in market development and is a member of the commercial team at Bruker Cellular Analysis. With a Ph.D. in Proteomics, his research focused on pathogen understanding through next-generation proteomics. For the past four years, he has been driving the promotion of Single Cell Functional platforms for Cell Therapy development and Antibody discovery, helping to advance cutting-edge solutions in the field.